[1] ZLOTNIK A,YOSHIE O.Chemokines:A new classification system and their role in immunity[J].Immunity,2000,12:121-127. [2] HUGHES C E,NIBBS R J B.A guide to chemokines and their receptors[J].FEBS,2018,285:2944-2971. [3] LIM HERMAN D.Systematic assessment of chemokine signaling at chemokine receptors CCR4,CCR7 and CCR10[J].International Journal of Molecular Sciences,2021,22(8):4232-4232. [4] TAMAGNE M,PAKDAMAN S,BARTOLUCCI P,et al.Whole-blood CCR7 expression and chemoattraction in red blood cell alloimmunization[J].British Journal of Haematology,2021,194(2):477-481. [5] COMERFORD I,HARATA-LEE Y,BUNTING M D,et al.A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system[J].Cytokine & Growth Factor Reviews,2013,24(3):269-283. [6] SANCHO M,VIEIRA J M,CASALOU C,et al.Expression and function of the chemokine receptor CCR7 in thyroid carcinomas[J].Journal of Endocrinology,2006,191(1):229-238. [7] SU M L,CHANG T M,CHIANG C H,et al.Inhibition of chemokine (C-C motif) receptor 7 sialylation suppresses CCL19-stimulated proliferation,invasion and anti-anoikis[J].PLoS One,2014,9(6):e98823. [8] MO M,ZHOU M,WANG L,et al.CCL21/CCR7 enhances the proliferation,migration,and invasion of human bladder cancer T24 cells[J].PLoS One,2015,10(3):e0119506. [9] BOYLE S T,INGMAN W V,POLTAVETS V,et al.The chemokine receptor CCR7 promotes mammary tumorigenesis through amplification of stem-like cells[J].Oncogene,2016,35(1):105-115. [10] BOYLE S T,GIENIEC K A,GREGOR C E,et al.Interplay between CCR7 and Notch1 axes promotes stemness in MMTV-PyMT mammary cancer cells[J].Molecular Cancer,2017,16(1):19. [11] CHEN Y,SHAO Z,JIANG E,et al.CCL21/CCR7 interaction promotes EMT and enhances the stemness of OSCC via a JAK2/STAT3 signaling pathway[J].Journal of Cellular Physiology,2020,235(9):5995-6009. [12] BIRKENBACH M,JOSEFSEN K,YALAMANCHILIR,et al.Epstein-Barr virus-induced genes:First lymphocyte-specific G protein-coupled peptide receptors[J].Journal of Virology,1993,67(4):2209-2220. [13] YOSHIDA R,NAGIRA M,KITAURA M,et al.Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7[J].Journal of Biological Chemistry,1998,273(12):7118-7122. [14] 程玉洁,刘 娟.趋化因子受体CCR7依赖的树突状细胞迁移的调控机制[J].中国免疫学杂志,2020,36(8):1004-1008. CHENG Y J,LIU J.Molecular regulation of CCR7-mediated dendritic cell migration[J].Chinese Journal of Immunology,2020,36(8):1004-1008.(in Chinese) [15] 吴学磊,王艳华.CCL21/CCR7轴与乳腺癌转移及治疗的相关研究进展[J].生物技术通讯,2019,30(3):425-429. WU X L,WANG Y H.Progress on the correlation between CCL21/CCR7 axis and breast cancer metastasis and therapy[J].Letters in Biotechnology,2019,30(3):425-429.(in Chinese) [16] 廖宇圣,张 姮,李 晖,等.CCR7在人肝癌组织中的表达及其与临床病理特征的关系[J].华中科技大学学报(医学版),2017,46(6):669-672. LIAO Y S,ZHANG H,LI H,et al.Expression of chemokine receptor CCR7 in human liver cancer tissues and its correlation with clinicopathological characteristics[J].Acta Medicinae Universitatis Scientiae et Technologiae Huazhong,2017,46(6):669-672.(in Chinese) [17] HAUSER M A,LEGLER D F.Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes[J].Journal of Leukocyte Biology,2016,99(6):869-882. [18] MISHAN M A,AHMADIANKIA N,BAHRAMI A R.CXCR4 and CCR7:Two eligible targets in targeted cancer therapy[J].Cell Biology International,2016,40(9):955-967. [19] CHIARA L D,CREAN J.Emerging transcriptional mechanisms in the regulation of epithelial to mesenchymal transition and cellular plasticity in the kidney[J].Journal of Clinical Medicine,2016,5(1):6. [20] ZHANG Y Y,LIU Z B,YE X G,et al.Iodine regulates G2M progression induced by CCL21 CCR7 interaction in primary cultures of papillary thyroid cancer cells with RET PTC expression[J].Molecular Medicine Reports,2016,14(4):3941-3946. [21] TANG F,CHEN J N,et al.Expression of CCL21 by EBV-associated gastric carcinoma cells protects CD8+CCR7+T lymphocytes from apoptosis via the mitochondria-mediated pathway[J].Pathology,2018,50(6):613-621. [22] 赵云霞,姜丽娜,赵 瑾.趋化因子受体 7 在乳腺癌组织中的表达及其与血管内皮生长因子-D 的关系[J].中国组织化学与细胞化学杂志,2018,27(5):440-445. ZHAO Y X,JIANG L N,ZHAO J.Expression of CCR7 in breast carcinoma and its relationship with vascular endothelial growth factor-D[J].Chinese Journal of Histochemistry and Cytochemistry,2018,27(5):440-445.(in Chinese) [23] 李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的表达及其临床意义[J].医学信息,2018,31(17):14-16. LI C L,PEI Y Z,ZOU Z T,et al.Expression of chemokine receptor CCR7 in non-small cell lung cancer and its clinical significance[J].Journal of Medical Information,2018,31(17):14-16.(in Chinese) [24] SALEM A.CCR7 as a therapeutic target in cancer[J].Biochimica et Biophysica Acta.Reviews on Cancer,2021,1875(1):188499. [25] 刘家齐,赵正晓,魏 颖,等.芍药苷对哮喘模型小鼠气道炎症趋化因子及受体的干预作用[J].中国实验动物学报,2016,24(5):460-464. LIU J Q,ZHAO Z X,WEI Y,et al.Inhibitory effect of paeoniflorin on inflammatory chemokines and their receptor in a mouse model of asthma[J].Acta Laboratorium Animalis Scientia Sinica,2016,24(5):460-464.(in Chinese) [26] 庞 捷,余克强.活动期类风湿关节炎患者外周血树突状细胞CCR5和CCR7的检测及意义[J]. 南方医科大学学报,2010,30(9):2067-2069. PANG J,YU K Q.Detection and its clinical value of CCR5 and CCR7 in dendritic cells from patients with active rheumatoid arthritis[J].Journal of Southern Medical University,2010,30(9):2067-2069.(in Chinese) [27] VAN R K.CCL21/CCR7 signaling in macrophages promotes joint inflammation and Th17-mediated osteoclast formation in rheumatoid arthritis[J].Cellular and Molecular Life Sciences,2020,77(7):1387-1399. [28] KAWASHIMA D.Augmented expression of secondary lymphoid tissue chemokine and EBI1 ligand chemokine in Crohn’s disease[J].Journal of Clinical Pathology,2005,58(10):1057-1063. |